Latest news

• Roche shares new positive Ocrevus data for MS patients

  The trial is a first-of-its-kind, open-label, phase 3b study evaluating the effect of Ocrevus in SPMS and PPMS patients. ... For 75% of patients diagnosed with SPMS and PPMS treated with Ocrevus, they showed no evidence of progression (NEP) after one year

• Roche’s Ocrevus shows significant benefit in early-stage MS patients

  The post-hoc analysis of the ORATORIO study also showed that Ocrevus treatment slowed accumulation of atrophied T2-lesion volume (aT2-LV) compared with placebo at 120 weeks in PPMS. ... According to Roche, those living with PPMS experience three to five

• Roche and NHS England hail pricing deal on MS drug Ocrevus

  The agreement means NICE can now reverse the rejection it announced in November, and Ocrevus(ocrelizumab), will be fully available to patients with primary progressive multiple sclerosis (PPMS) in England, the ... England's contribution to its revenues

• Dismay as NICE rejects Roche’s MS drug Ocrevus

  and NICE to reach an agreement that will allow the drug to be covered for PPMS. ... We ask that NICE are given the flexibility to consider an indication-specific price for ocrelizumab in PPMS.”.

• Daily Brief: Tecentriq set for breast cancer filing, Ocrevus gets NICE thumbs down, NHS needs more cash

  NICE says no to Ocrevus in primary progressive MS. On Friday NICE announced that it would not recommend Roche; s Ocrevus (ocrelizumab) for treating primary progressive multiple sclerosis (PPMS) in adults. ... Ocrevus is the only drug approved for PPMS,